Do analysts prefer QDEL or UFPT?

QuidelOrtho currently has a consensus target price of $13.63, indicating a potential upside of 26.51%. Given QuidelOrtho's higher probable upside, analysts plainly believe QuidelOrtho is more favorable than UFP Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score QuidelOrtho 3 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 UFP Technologies 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer QDEL or UFPT?

In the previous week, QuidelOrtho and QuidelOrtho both had 1 articles in the media. QuidelOrtho's average media sentiment score of 1.67 beat UFP Technologies' score of 0.37 indicating that QuidelOrtho is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment QuidelOrtho 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive UFP Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer QDEL or XRAY?

In the previous week, DENTSPLY SIRONA had 3 more articles in the media than QuidelOrtho. MarketBeat recorded 4 mentions for DENTSPLY SIRONA and 1 mentions for QuidelOrtho. QuidelOrtho's average media sentiment score of 1.67 beat DENTSPLY SIRONA's score of -0.15 indicating that QuidelOrtho is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment QuidelOrtho 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive DENTSPLY SIRONA 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate QDEL or AVNS?

QuidelOrtho currently has a consensus price target of $13.63, indicating a potential upside of 26.51%. Given QuidelOrtho's higher possible upside, equities analysts clearly believe QuidelOrtho is more favorable than Avanos Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score QuidelOrtho 3 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Avanos Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media refer more to QDEL or AVNS?

In the previous week, QuidelOrtho and QuidelOrtho both had 1 articles in the media. Avanos Medical's average media sentiment score of 1.73 beat QuidelOrtho's score of 1.67 indicating that Avanos Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment QuidelOrtho 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Avanos Medical 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher earnings & valuation, CERS or QDEL?

Cerus has higher earnings, but lower revenue than QuidelOrtho. Cerus is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cerus $206.13M 2.23 -$15.63M -$0.03 N/A QuidelOrtho $2.73B 0.27 -$1.13B -$15.41 N/A

Is CERS or QDEL more profitable?

Cerus has a net margin of -3.06% compared to QuidelOrtho's net margin of -39.20%. QuidelOrtho's return on equity of 4.88% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets Cerus -3.06% -10.19% -3.14% QuidelOrtho -39.20% 4.88% 1.63%

Does the media prefer CERS or QDEL?

In the previous week, Cerus and Cerus both had 1 articles in the media. QuidelOrtho's average media sentiment score of 1.67 beat Cerus' score of 1.09 indicating that QuidelOrtho is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cerus 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive QuidelOrtho 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is EMBC or QDEL more profitable?

Embecta has a net margin of 8.59% compared to QuidelOrtho's net margin of -39.20%. QuidelOrtho's return on equity of 4.88% beat Embecta's return on equity. Company Net Margins Return on Equity Return on Assets Embecta 8.59% -19.25% 10.82% QuidelOrtho -39.20% 4.88% 1.63%

Does the media prefer EMBC or QDEL?

In the previous week, Embecta had 2 more articles in the media than QuidelOrtho. MarketBeat recorded 3 mentions for Embecta and 1 mentions for QuidelOrtho. QuidelOrtho's average media sentiment score of 1.67 beat Embecta's score of 0.00 indicating that QuidelOrtho is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Embecta 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral QuidelOrtho 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

QuidelOrtho (QDEL) Competitors

$10.77 +0.39 (+3.76%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$10.81 +0.04 (+0.37%)

As of 10/2/2026 07:59 PM Eastern

Compare

QDEL vs. UFPT, XRAY, AVNS, CERS, and EMBC

Should you buy QuidelOrtho stock or one of its competitors? QuidelOrtho's main competitors and comparable companies include UFP Technologies (UFPT), DENTSPLY SIRONA (XRAY), Avanos Medical (AVNS), Cerus (CERS), and Embecta (EMBC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does QuidelOrtho compare to UFP Technologies?

QuidelOrtho (NASDAQ:QDEL) and UFP Technologies (NASDAQ:UFPT) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

UFP Technologies has a net margin of 11.45% compared to QuidelOrtho's net margin of -39.20%. UFP Technologies' return on equity of 18.42% beat QuidelOrtho's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
QuidelOrtho	-39.20%	4.88%	1.63%
UFP Technologies	11.45%	18.42%	11.96%

In the previous week, QuidelOrtho and QuidelOrtho both had 1 articles in the media. QuidelOrtho's average media sentiment score of 1.67 beat UFP Technologies' score of 0.37 indicating that QuidelOrtho is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
QuidelOrtho	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
UFP Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

QuidelOrtho currently has a consensus target price of $13.63, indicating a potential upside of 26.51%. Given QuidelOrtho's higher probable upside, analysts plainly believe QuidelOrtho is more favorable than UFP Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
UFP Technologies	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

QuidelOrtho has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, UFP Technologies has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market.

UFP Technologies has lower revenue, but higher earnings than QuidelOrtho. QuidelOrtho is trading at a lower price-to-earnings ratio than UFP Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
QuidelOrtho	$2.73B	0.27	-$1.13B	-$15.41	N/A
UFP Technologies	$602.80M	3.87	$68.31M	$9.28	32.40

99.0% of QuidelOrtho shares are held by institutional investors. Comparatively, 87.3% of UFP Technologies shares are held by institutional investors. 1.1% of QuidelOrtho shares are held by company insiders. Comparatively, 4.6% of UFP Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

UFP Technologies beats QuidelOrtho on 10 of the 14 factors compared between the two stocks.

How does QuidelOrtho compare to DENTSPLY SIRONA?

QuidelOrtho (NASDAQ:QDEL) and DENTSPLY SIRONA (NASDAQ:XRAY) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

DENTSPLY SIRONA has higher revenue and earnings than QuidelOrtho. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
QuidelOrtho	$2.73B	0.27	-$1.13B	-$15.41	N/A
DENTSPLY SIRONA	$3.68B	0.47	-$598M	-$2.75	N/A

In the previous week, DENTSPLY SIRONA had 3 more articles in the media than QuidelOrtho. MarketBeat recorded 4 mentions for DENTSPLY SIRONA and 1 mentions for QuidelOrtho. QuidelOrtho's average media sentiment score of 1.67 beat DENTSPLY SIRONA's score of -0.15 indicating that QuidelOrtho is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
QuidelOrtho	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
DENTSPLY SIRONA	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

DENTSPLY SIRONA has a net margin of -14.99% compared to QuidelOrtho's net margin of -39.20%. DENTSPLY SIRONA's return on equity of 20.84% beat QuidelOrtho's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
QuidelOrtho	-39.20%	4.88%	1.63%
DENTSPLY SIRONA	-14.99%	20.84%	5.32%

99.0% of QuidelOrtho shares are held by institutional investors. Comparatively, 95.7% of DENTSPLY SIRONA shares are held by institutional investors. 1.1% of QuidelOrtho shares are held by company insiders. Comparatively, 0.5% of DENTSPLY SIRONA shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

QuidelOrtho has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, DENTSPLY SIRONA has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

QuidelOrtho presently has a consensus price target of $13.63, suggesting a potential upside of 26.51%. DENTSPLY SIRONA has a consensus price target of $13.31, suggesting a potential upside of 53.49%. Given DENTSPLY SIRONA's stronger consensus rating and higher probable upside, analysts clearly believe DENTSPLY SIRONA is more favorable than QuidelOrtho.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
DENTSPLY SIRONA	3 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

DENTSPLY SIRONA beats QuidelOrtho on 12 of the 16 factors compared between the two stocks.

How does QuidelOrtho compare to Avanos Medical?

QuidelOrtho (NASDAQ:QDEL) and Avanos Medical (NYSE:AVNS) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

In the previous week, QuidelOrtho and QuidelOrtho both had 1 articles in the media. Avanos Medical's average media sentiment score of 1.73 beat QuidelOrtho's score of 1.67 indicating that Avanos Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
QuidelOrtho	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Avanos Medical	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

QuidelOrtho has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, Avanos Medical has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market.

Avanos Medical has a net margin of -10.39% compared to QuidelOrtho's net margin of -39.20%. Avanos Medical's return on equity of 5.39% beat QuidelOrtho's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
QuidelOrtho	-39.20%	4.88%	1.63%
Avanos Medical	-10.39%	5.39%	3.97%

99.0% of QuidelOrtho shares are owned by institutional investors. Comparatively, 95.2% of Avanos Medical shares are owned by institutional investors. 1.1% of QuidelOrtho shares are owned by company insiders. Comparatively, 2.3% of Avanos Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

QuidelOrtho currently has a consensus price target of $13.63, indicating a potential upside of 26.51%. Given QuidelOrtho's higher possible upside, equities analysts clearly believe QuidelOrtho is more favorable than Avanos Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Avanos Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Avanos Medical has lower revenue, but higher earnings than QuidelOrtho. Avanos Medical is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
QuidelOrtho	$2.73B	0.27	-$1.13B	-$15.41	N/A
Avanos Medical	$715.90M	1.64	-$72.90M	-$1.61	N/A

Summary

Avanos Medical beats QuidelOrtho on 9 of the 13 factors compared between the two stocks.

How does QuidelOrtho compare to Cerus?

Cerus (NASDAQ:CERS) and QuidelOrtho (NASDAQ:QDEL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Cerus currently has a consensus target price of $5.25, indicating a potential upside of 130.26%. QuidelOrtho has a consensus target price of $13.63, indicating a potential upside of 26.51%. Given Cerus' stronger consensus rating and higher probable upside, equities analysts plainly believe Cerus is more favorable than QuidelOrtho.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Cerus and Cerus both had 1 articles in the media. QuidelOrtho's average media sentiment score of 1.67 beat Cerus' score of 1.09 indicating that QuidelOrtho is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cerus	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
QuidelOrtho	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

78.4% of Cerus shares are owned by institutional investors. Comparatively, 99.0% of QuidelOrtho shares are owned by institutional investors. 5.3% of Cerus shares are owned by company insiders. Comparatively, 1.1% of QuidelOrtho shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Cerus has a beta of 1.83, meaning that its share price is 83% more volatile than the broader market. Comparatively, QuidelOrtho has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

Cerus has a net margin of -3.06% compared to QuidelOrtho's net margin of -39.20%. QuidelOrtho's return on equity of 4.88% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerus	-3.06%	-10.19%	-3.14%
QuidelOrtho	-39.20%	4.88%	1.63%

Cerus has higher earnings, but lower revenue than QuidelOrtho. Cerus is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$206.13M	2.23	-$15.63M	-$0.03	N/A
QuidelOrtho	$2.73B	0.27	-$1.13B	-$15.41	N/A

Summary

Cerus beats QuidelOrtho on 9 of the 15 factors compared between the two stocks.

How does QuidelOrtho compare to Embecta?

Embecta (NASDAQ:EMBC) and QuidelOrtho (NASDAQ:QDEL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

Embecta has higher earnings, but lower revenue than QuidelOrtho. QuidelOrtho is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.08B	0.30	$95.40M	$1.48	3.82
QuidelOrtho	$2.73B	0.27	-$1.13B	-$15.41	N/A

In the previous week, Embecta had 2 more articles in the media than QuidelOrtho. MarketBeat recorded 3 mentions for Embecta and 1 mentions for QuidelOrtho. QuidelOrtho's average media sentiment score of 1.67 beat Embecta's score of 0.00 indicating that QuidelOrtho is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Embecta	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
QuidelOrtho	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

93.8% of Embecta shares are owned by institutional investors. Comparatively, 99.0% of QuidelOrtho shares are owned by institutional investors. 1.3% of Embecta shares are owned by company insiders. Comparatively, 1.1% of QuidelOrtho shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Embecta has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market. Comparatively, QuidelOrtho has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market.

Embecta has a net margin of 8.59% compared to QuidelOrtho's net margin of -39.20%. QuidelOrtho's return on equity of 4.88% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Embecta	8.59%	-19.25%	10.82%
QuidelOrtho	-39.20%	4.88%	1.63%

Embecta currently has a consensus target price of $11.00, indicating a potential upside of 94.69%. QuidelOrtho has a consensus target price of $13.63, indicating a potential upside of 26.51%. Given Embecta's stronger consensus rating and higher probable upside, equities analysts plainly believe Embecta is more favorable than QuidelOrtho.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Embecta beats QuidelOrtho on 11 of the 15 factors compared between the two stocks.

Get QuidelOrtho News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QDEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QDEL vs. The Competition

Export

Metric	QuidelOrtho	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$738.55M	$5.48B	$7.15B	$13.28B
Dividend Yield	N/A	1.81%	2.54%	17.33%
P/E Ratio	-0.70	25.42	274.71	26.04
Price / Sales	0.27	67.70	656.46	105.16
Price / Cash	0.57	32.27	78.87	52.62
Price / Book	0.38	5.73	10.93	6.31
Net Income	-$1.13B	$152.68M	$3.51B	$362.16M
7 Day Performance	-1.55%	-1.71%	-2.00%	-1.66%
1 Month Performance	-22.91%	-4.87%	-6.19%	-4.68%
1 Year Performance	-64.08%	1.30%	8.03%	1.57%

QuidelOrtho Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QDEL QuidelOrtho	3.028 of 5 stars	$10.77 +3.8%	$13.63 +26.5%	-64.1%	$738.55M	$2.73B	N/A	6,500	Positive News Gap Up
UFPT UFP Technologies	1.0054 of 5 stars	$299.22 +1.2%	N/A	+54.0%	$2.29B	$602.80M	32.24	5,349
XRAY DENTSPLY SIRONA	3.2084 of 5 stars	$9.28 -1.3%	$13.31 +43.4%	-34.3%	$1.87B	$3.68B	N/A	14,000
AVNS Avanos Medical	0.4135 of 5 stars	$24.99 flat	N/A	N/A	$1.17B	$715.90M	N/A	4,040	Positive News
CERS Cerus	1.858 of 5 stars	$2.45 -6.5%	$5.25 +114.3%	+45.2%	$527.99M	$206.13M	N/A	345	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QDEL) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

QuidelOrtho (QDEL) Competitors

QDEL vs. UFPT, XRAY, AVNS, CERS, and EMBC

How does QuidelOrtho compare to UFP Technologies?

Summary

How does QuidelOrtho compare to DENTSPLY SIRONA?

Summary

How does QuidelOrtho compare to Avanos Medical?

Summary

How does QuidelOrtho compare to Cerus?

Summary

How does QuidelOrtho compare to Embecta?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QDEL vs. The Competition

QuidelOrtho Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

QuidelOrtho (QDEL) Competitors

QDEL vs. UFPT, XRAY, AVNS, CERS, and EMBC

How does QuidelOrtho compare to UFP Technologies?

Is QDEL or UFPT more profitable?

Does the media prefer QDEL or UFPT?

Do analysts prefer QDEL or UFPT?

Which has more volatility and risk, QDEL or UFPT?

Which has preferable valuation & earnings, QDEL or UFPT?

Do institutionals & insiders have more ownership in QDEL or UFPT?

Summary

How does QuidelOrtho compare to DENTSPLY SIRONA?

Which has higher valuation and earnings, QDEL or XRAY?

Does the media prefer QDEL or XRAY?

Is QDEL or XRAY more profitable?

Do insiders and institutionals hold more shares of QDEL or XRAY?

Which has more risk and volatility, QDEL or XRAY?

Do analysts rate QDEL or XRAY?

Summary

How does QuidelOrtho compare to Avanos Medical?

Does the media refer more to QDEL or AVNS?

Which has more volatility & risk, QDEL or AVNS?

Is QDEL or AVNS more profitable?

Do insiders and institutionals have more ownership in QDEL or AVNS?

Do analysts rate QDEL or AVNS?

Which has preferable valuation & earnings, QDEL or AVNS?

Summary

How does QuidelOrtho compare to Cerus?

Do analysts rate CERS or QDEL?

Does the media prefer CERS or QDEL?

Do insiders and institutionals believe in CERS or QDEL?

Which has more risk and volatility, CERS or QDEL?

Is CERS or QDEL more profitable?

Which has higher earnings & valuation, CERS or QDEL?

Summary

How does QuidelOrtho compare to Embecta?

Which has preferable earnings and valuation, EMBC or QDEL?

Does the media prefer EMBC or QDEL?

Do institutionals and insiders have more ownership in EMBC or QDEL?

Which has more risk and volatility, EMBC or QDEL?

Is EMBC or QDEL more profitable?

Do analysts prefer EMBC or QDEL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QDEL vs. The Competition

QuidelOrtho Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools